The Prognosis of Patients After PCI：a Multi-center Study in China

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

2400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-11-01

Study Completion Date

2027-11-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Coronary artery disease (CAD) is caused by myocardial ischemia, hypoxia or necrosis due to coronary artery stenosis, spasm or obstruction. Although standard drug therapy can greatly improve the prognosis of patients with CAD after percutaneous coronary interventions (PCI), these patients are still at high risk of major adverse cardiovascular and cerebrovascular events (MACCE). At present, the concept of residual inflammation risk (RIR) has aroused widespread concern. RIR is an important independent risk in patients with CAD. Previous studies indicated that hsCRP ≥ 2mg / L was the definition standard of RIR in CAD in European and American people. In China, the impact of dynamic changes of hsCRP and other inflammatory factors on MACCE in PCI population remains unclear. Therefore, in this study, the investigators plan to recruit patients undergoing PCI, and observe the impact of hsCRP and other inflammatory factors on the prognosis of these patients during long term follow-up at 17 hospitals in China.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

International Post-PCI FFR Extended Registry

NCT05672862

Coronary Disease

COMPLETED

Precision Therapy in Complex High-risk Coronary Artery Disease

NCT04444960

Coronary Artery Disease

UNKNOWN

PCI in Beijing Friendship Hospital

NCT05728580

Cardiovascular Diseases Percutaneous Coronary Intervention

RECRUITING

National Multicenter Cohort Registry Study of Rapid rEcurrences of Coronary Unexplained In-stent Restenosis

NCT05437965

Coronary Artery Disease Arteritis In-Stent Stenosis (Restenosis) of Coronary Artery Stent

RECRUITING

Prognostic Impact of PMI in Stable CAD Undergoing PCI

NCT04239404

Periprocedural Myocardial Injury Coronary Artery Disease Percutaneous Coronary Intervention

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Inflammation

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participants who understand and sign the informed consent voluntarily;
* Age ≥ 18 years old and ≤ 80 years old, regardless of sex;
* The hospitalized patients with coronary heart disease undergoing PCI;
* Complete all planned PCI during hospitalization.

Exclusion Criteria

* Acute, chronic or recurrent infectious diseases;
* Immune diseases or immune-related diseases;
* Long-term use of non-steroidal anti-inflammatory drugs, hormones, immunomodulatory and chemotherapy drugs;
* Pregnant women, lactating women or women of childbearing age who do not use effective contraceptive measures;
* The researchers determined that other conditions in which the patient was not suitable to participate in the clinical trial.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No